RIGL - 2.50 Pre-market at 2.82/2.83 FDA Accepts Rigel's New Drug Application for TAVALISSE™ (fostamatinib disodium) for the Treatment of Chronic ITP http://stockcharts.com/c-sc/sc?s=RIGL&p=D&b=5&g=0&i=t97775619946&r=1497874835651 http://stockcharts.com/c-sc/sc?s=RIGL&p=W&b=5&g=0&i=t03529986082&r=1497874811043